For research use only
| Cat No. | ABC-TC0006 |
| Product Type | Human Bladder Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Bladder Cancer |
| Product Code | 253JB-V; 253J B-V; 253JBV; 253J-Bladder-V |
Tumorigenecity: Isoenzyme: Histopathology: bladder cancerSubculture: Split ratio: Media change: Reverse transcritase: Production
253J-BV is a highly metastatic human bladder carcinoma cell line derived from the parental 253J line by serial in vivo selection for spontaneous metastasis following orthotopic implantation in athymic nude mice. Both lines originate from a grade II transitional cell carcinoma of the bladder in a 53-year-old Caucasian male. 253J-BV cells retain epithelial morphology but exhibit enhanced motility and mesenchymal features. The cells grow as an adherent monolayer under standard conditions. Karyotype analysis reveals complex chromosomal abnormalities similar to those observed in aggressive urothelial tumors. Unlike the parental line, 253J-BV cells are capable of forming both primary tumors and spontaneous distant metastases, particularly to the lungs, following orthotopic inoculation. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | 253JB-V; 253J B-V; 253JBV; 253J-Bladder-V |
| Species | Human |
| Cat.No | ABC-TC0006 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Bladder Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Bladder Cancer Cell Lines |
| Stock | Out of stock |
253J-BV is an advanced model for studying metastatic bladder cancer and epithelial-to-mesenchymal transition (EMT). It is widely used in comparative studies with 253J to identify molecular determinants of tumor invasion, motility, and metastasis. Researchers also use 253J-BV in preclinical evaluations of anti-metastatic therapies, signaling pathway inhibitors, and transcriptional regulators associated with metastatic progression.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
